The FDA has not approved any SGLT2 inhibitor or GLP-1 receptor agonist for type 1 diabetes, but their use in this patient population may continue due to the significant weight management and cardiorenal benefits observed in people with and without type 2 diabetes. In their study, the researchers noted that the differences in characteristics for patients prescribed these drug suggest their use was intended to address additional medical needs. From 2010 to 2023, the percentage of type 1 diabetes patients prescribed an agent from one of these two classes increased from 0.7% to 8.3%, with the bulk of the increase driven by GLP-1 agonists, reported Hui Shao, MD, PhD, of Emory University Rollins School of Public Health in Atlanta, and colleagues
Discover what IV therapy and IV drip treatments can do for hydration, recovery, and wellness
Notable weight losses were achieved in both non-CKD and CKD patients
This isnt Wegovy-specific, but worth flagging to your GP if you take an anxiety or depression medication alongside Wegovy
PlexusDx sources compounded tirzepatide from licensed 503A facilities with flat monthly pricing across three commitment tiers: month-to-month, 3-month, and 6-month plans